INS and Hyperglycemia: The incidence of T1D is rising rapidly with a predicted increase in paediatric cases of 70% over the next 15 years in Europe.1 The aetiology of T1D is the autoimmune (loss of self-tolerance)-mediated destruction of insulin-producing pancreatic β cells leading to insulin deficiency and development of hyperglycaemia.2 At present, medical management of T1D focuses on intensive insulin replacement therapy to limit microvascular complications (retinopathy, nephropathy, neuropathy).